6 results about "Enterovirus 71" patented technology

The application discloses a high-specificity and high-affinity monoclonal antibody and antigen-binding fragment thereof for recognizing enterovirus 71 capsid protein VP1. The amino acid sequence of the heavy chain variable region of the antibody is shown as SEQ ID NO. 1, and the amino acid sequence of the light chain variable region is shown as SEQ ID NO. 5. The monoclonal antibody or antigen-binding fragment thereof can be used for qualitative and quantitative detection of enterovirus 71 VP1 protein.

A method of detecting severe disease-associated mutations in an enterovirus 71 (EV-A71), comprising: performing an assay on a test sample containing an EV-A71 genomic RNA, a fragment thereof or an amplicon thereof, or an EV-A71 VP1 protein or fragment thereof to detect one or more severe disease-associated mutations in the EV-A71 genomic RNA, the fragment thereof or the amplicon thereof, or the EV-A71 protein or fragment thereof, wherein the one or more mutations are selected from mutations at positions corresponding to 5′ UTR nucleotide positions C580, A707, and C709 in an EV-A71 5′ UTR nucleic acid sequence and at residues corresponding to A280 and E145 in an EV-A71 VP1 protein sequence.

The application relates to the field of microbial technology, in particular to construction and application of a virus strain with mutation of the 75th amino acid of VP1 protein of enterovirus 71. The amino acid sequence of the mutant of VP1 protein of enterovirus 71 is shown in SEQ ID NO. 1. The mutant of VP1 protein and the corresponding coding nucleic acid molecule can make the proliferation ability of enterovirus 71 decrease, but the virulence in mice increases, and can be used for constructing the mutant virus strain of enterovirus 71, and providing effective biological materials for preparing medicines for preventing and treating enterovirus 71 infection and screening and quality control of the medicines.

The disclosure provides a mutant of enterovirus 71 and a virus-like particle thereof, and relates to the field of biological medicine.The virus-like particle of enterovirus 71 in the disclosure is obtained by modifying the structural genes VP0, VP1 and VP3 of the virus capsid protein by using computational structural biology, and completing self-assembly in vivo by a Hansenula polymorpha expression system.The mutant of enterovirus 71 and the virus-like particle thereof in the disclosure can significantly improve immunogenicity compared with the unmodified one, and have a high clinical application prospect.

The invention belongs to the technical field of antiviral drugs, and relates to preparation of a 2, 4, 5-polysubstituted pyrimidine derivative and application of the 2, 4, 5-polysubstituted pyrimidine derivative in resisting enterovirus 71. The anti-EV71 activity research experiment of the pyrimidine derivative shows that the pyrimidine derivative has certain inhibitory activity on EV71: the pyrimidine derivative inhibits the cytopathic effect (CPE) generated by EV71 on a host cell Vero, enhances the cell survival rate and reduces the progeny virus yield; host cell lesions caused by EV71 infection can be inhibited, and the method mainly acts on a replication and proliferation stage of EV71 in host cells; therefore, the novel pyrimidine derivatives have the potential of preparing the anti-EV71 virus medicine.

The application discloses a new medical application of astragaloside, in particular, a new medical application of astragaloside in enhancing the anti-enterovirus 71 type of curcumin. Researches show that EV71 infection causes the activity of human normal GES-1 cells to decrease, and the use of curcumin in the infected cells needs to reach a certain concentration to show obvious antiviral effect, and the use of astragaloside and curcumin in combination can show better antiviral effect under the use of lower concentration of curcumin, and the role of astragaloside in enhancing the anti-EV71 of curcumin is determined, and a foundation is laid for the combination of astragaloside and curcumin in preventing and treating hand-foot-mouth disease caused by EV71 infection.